The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada-Reference-Cited by-同舟云学术

The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada

Published:2021-01-01 Issue:1 Volume:24 Page:150-161
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Hu Yannan¹,Charaan Majed²,van Oostrum Ilse¹,Heeg Bart¹^ORCID,Bell Timothy³

Affiliation:

1. Ingress-Health, Rotterdam, the Netherlands

2. Pfizer Canada Inc, Quebec, Canada

3. Pfizer Inc, New York, USA

Funder

Pfizer

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1875743

Reference32 articles.

1. Molecular prognostic factors in cytogenetically normal acute myeloid leukemia

2. Acute Myeloid Leukemia

3. Challenges in Treating Older Patients with Acute Myeloid Leukemia

4. Treating acute myeloid leukemia in older adults

5. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glasdigib fails to slay the hedgehog in pivotal AML trials;Leukemia;2023-10-10

2. A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia;Expert Review of Hematology;2022-09-02

3. Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy;Expert Opinion on Pharmacotherapy;2021-12-14